<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03391401</url>
  </required_header>
  <id_info>
    <org_study_id>2017110</org_study_id>
    <nct_id>NCT03391401</nct_id>
  </id_info>
  <brief_title>Investigation of Microbiome-based Prognostical Biomarkers in Patients With Morbid Obesity and Bariatric Surgery</brief_title>
  <official_title>Investigation of Microbiome-based Prognostical Biomarkers in Patients With Morbid Obesity and Bariatric Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Franziskus Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Bonn</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Franziskus Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Morbid obesity leads to non-alcoholic fatty liver disease (NAFLD), and not all NAFLD cases
      benefit from weight loss e.g. after bariatric surgery. Our aim is to find out, which
      intrahepatic factors and / or biomarkers might be beneficial or can be identified as
      prognostic factors for remission of NAFLD after weight loss. As other factors such as the
      microbiome or muscle and fatty tissue also influence the development of obesity and liver
      diseases, it is planned to examine these parameters before and after bariatric surgery as
      well.

      Tissue biopsies will therefore be taken during the surgery, and blood as well as stool
      samples will be collected and compared for suitable biomarkers before and after the
      intervention.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 15, 2018</start_date>
  <completion_date type="Anticipated">July 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of microbiome after bariatric surgery</measure>
    <time_frame>at time of operation, 3 and 6 months after the operation</time_frame>
    <description>Collection of stool sample before and after (3 and 6 months) the operation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes of microbiome after bariatric surgery</measure>
    <time_frame>at time of operation, 3 and 6 months after the operation</time_frame>
    <description>Collection of blood sample before and after (3 and 6 months) the operation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of fatty liver in obese patients</measure>
    <time_frame>during the operation</time_frame>
    <description>Surgical liver biopsy during laparoscopy</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Obesity, Morbid</condition>
  <condition>Bariatric Surgery Candidate</condition>
  <condition>NAFLD</condition>
  <condition>Microbiome</condition>
  <arm_group>
    <arm_group_label>Adip1</arm_group_label>
    <description>Patients with morbid obesity (i.e. BMI &gt;35 kg/sqm) and age &gt;18 scheduled for bariatric surgery (all standard procedures included)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bariatric surgery</intervention_name>
    <description>Any bariatric operation that is considered as a standard procedure in bariatric surgery (i.e. sleeve gastrectomy, roux-en-y gastric bypass, mini-gastric / one anastomosis gastric bypass, redo and revisional bariatric surgery).</description>
    <arm_group_label>Adip1</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Hair samples, blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult Patients with the above given criteria that are willing to treat their morbid obesity
        by bariatric surgery and have at least absolved 3 months of failed conservative treatment
        for morbid obesity, have shown to have good long-time compliance and high motivation.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI above 40 kg/sqm or

          -  BMI above 35 kg/sqm and comorbidities related to morbid obesity (e.g. type 2 diabetes,
             hypertension, coronary heart disease, dyslipoproteinemia, sleep apnea, and others

        Exclusion Criteria:

          -  BMI below 35 kg/sqm

          -  no informed consent

          -  patient not suitable for bariatric surgery (severe psychological disorder, pregnancy,
             drug abuse, active malignant or other consuming disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Karl P Rheinwalt, MD</last_name>
    <phone>+49-5591</phone>
    <phone_ext>1128</phone_ext>
    <email>karlpeter.rheinwalt@cellitinnen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andreas Plamper, MD</last_name>
    <phone>+49-5591</phone>
    <phone_ext>1126</phone_ext>
    <email>andreas.plamper@cellitinnen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Franziskus-Hospital</name>
      <address>
        <city>Cologne</city>
        <zip>50825</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karl P Rheinwalt, MD</last_name>
      <phone>+49-221-5591</phone>
      <phone_ext>1128</phone_ext>
      <email>karlpeter.rheinwalt@cellitinnen.de</email>
    </contact>
    <contact_backup>
      <last_name>Andreas Plamper, MD</last_name>
      <phone>+49-221-5591</phone>
      <phone_ext>1126</phone_ext>
      <email>andreas.plamper@cellitinnen.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Li Z, Bowerman S, Heber D. Health ramifications of the obesity epidemic. Surg Clin North Am. 2005 Aug;85(4):681-701, v. Review.</citation>
    <PMID>16061080</PMID>
  </results_reference>
  <results_reference>
    <citation>Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D; Million Women Study Collaboration. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007 Dec 1;335(7630):1134. Epub 2007 Nov 6.</citation>
    <PMID>17986716</PMID>
  </results_reference>
  <results_reference>
    <citation>Sjöström L, Peltonen M, Jacobson P, Sjöström CD, Karason K, Wedel H, Ahlin S, Anveden Å, Bengtsson C, Bergmark G, Bouchard C, Carlsson B, Dahlgren S, Karlsson J, Lindroos AK, Lönroth H, Narbro K, Näslund I, Olbers T, Svensson PA, Carlsson LM. Bariatric surgery and long-term cardiovascular events. JAMA. 2012 Jan 4;307(1):56-65. doi: 10.1001/jama.2011.1914.</citation>
    <PMID>22215166</PMID>
  </results_reference>
  <results_reference>
    <citation>Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013 Nov;10(11):686-90. doi: 10.1038/nrgastro.2013.171. Epub 2013 Sep 17. Review.</citation>
    <PMID>24042449</PMID>
  </results_reference>
  <results_reference>
    <citation>Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004 Oct 13;292(14):1724-37. Review. Erratum in: JAMA. 2005 Apr 13;293(14):1728.</citation>
    <PMID>15479938</PMID>
  </results_reference>
  <results_reference>
    <citation>Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, Thaiss CA, Kau AL, Eisenbarth SC, Jurczak MJ, Camporez JP, Shulman GI, Gordon JI, Hoffman HM, Flavell RA. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012 Feb 1;482(7384):179-85. doi: 10.1038/nature10809.</citation>
    <PMID>22297845</PMID>
  </results_reference>
  <results_reference>
    <citation>Fujisaka S, Ussar S, Clish C, Devkota S, Dreyfuss JM, Sakaguchi M, Soto M, Konishi M, Softic S, Altindis E, Li N, Gerber G, Bry L, Kahn CR. Antibiotic effects on gut microbiota and metabolism are host dependent. J Clin Invest. 2016 Dec 1;126(12):4430-4443. doi: 10.1172/JCI86674. Epub 2016 Oct 24.</citation>
    <PMID>27775551</PMID>
  </results_reference>
  <results_reference>
    <citation>Mathis D. Immunological goings-on in visceral adipose tissue. Cell Metab. 2013 Jun 4;17(6):851-9. doi: 10.1016/j.cmet.2013.05.008. Review.</citation>
    <PMID>23747244</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2017</study_first_submitted>
  <study_first_submitted_qc>December 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2018</study_first_posted>
  <last_update_submitted>December 29, 2017</last_update_submitted>
  <last_update_submitted_qc>December 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Franziskus Hospital</investigator_affiliation>
    <investigator_full_name>Andreas Plamper</investigator_full_name>
    <investigator_title>Assistant study director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

